KR20040012888A - 세포 이동성 검사 - Google Patents
세포 이동성 검사 Download PDFInfo
- Publication number
- KR20040012888A KR20040012888A KR10-2003-7015768A KR20037015768A KR20040012888A KR 20040012888 A KR20040012888 A KR 20040012888A KR 20037015768 A KR20037015768 A KR 20037015768A KR 20040012888 A KR20040012888 A KR 20040012888A
- Authority
- KR
- South Korea
- Prior art keywords
- cell migration
- chemokine
- ligand
- receptor
- antagonist
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
- G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5029—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell motility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Steroid Compounds (AREA)
- Spectrometry And Color Measurement (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
수용체 | 리간드 예2 |
BLT1 | 루코트리엔 B4 |
PDGFR | 혈소판-유도된 생장 인자 |
FPR | fMLP |
FPR1 | 모름 |
FMLP 수용체-유사 수용체 | 모름 |
CRTH2 | 프로스타글란딘2 |
C3aR | C3a |
C5aR | C5a |
Noci-R | 노시페틴 |
EDG 패밀리 | 스핑고신 1-인산염 |
CB1 | 카나비노이드 |
VEGFR | 맥관 내피 생장 인자 |
EGFR | 상피 생장 인자 |
FGFR | 섬유아세포 생장 인자 |
P2Y 수용체 | P2Y |
CTR | 칼시토닌 |
CRLR | 칼시토닌 유전자관련 펩티드(CGRP) |
히스타민 수용체 | 히스타민 |
트롬빈 수용체 | 트롬빈 |
TrkB | 뇌-유도된 신경성 생장인자(BDNF) |
1화학친화성물질 수용체는 완벽한 것은 아니다.2각 수용체에 대한 일부 리간드의 예만을 제공한다.이 목록이 완벽하다는 것을 의미하는 것은 아니다. |
수용체 | 사람 리간드 |
CXCR1 | IL-8, GCP-2 |
CXCR2 | IL-8, GCP-2, Gro α, Gro β, Gro γ, ENA-78, PBP |
CXCR3 | MIG IP-10, I-TAC |
CXCR4 | SDF-1/PBSF |
CXCR5 | BLC/BCA-1 |
CCR1 | MIP-1α, MIP1-β, RANTES, HCC-1,2,3, and 4 |
CCR2 | MCP-2, MCP-2, MCP-3, MCP-4 |
CCR3 | eotaxin-1, eotaxin-2, MCP-3 |
CCR4 | TARC, MDC, MIP-1α, RANTES |
CCR5 | MIP-1α MIP-1β, RANTES |
CCR6 | MIP-3α/LARC |
CCR7 | MIP-3β/ELC, 6Ckine/LC |
CCR8 | I-309 |
CCR9 | TECK |
XCR1 | 임포택틴 |
CX3CR1 | 프랙트알킨/뉴우로택틴 |
CXCR6 | CXCL16 |
CCR10 | CTACK |
길항체1 | 수용체 | 리간드 | 세포 |
RAMAG-1 | CXCR3 | I-TAC(250nM),IP-10 | 활성화된 사람 임파세포 |
RAMAG-2 | CXCR4 | SDF-1 | CXCR4를 발현시키는 MOLT-4 세포(사람 T 임파아구; AmericanType Tissue Collection(ATCC);Manassas, VA) |
RAMAG-3 | CCR1 | MIP-1α | THP-1 세포(사람 단세포; ATCC) |
1통상적인 세포 이동 검사를 이용하여 확인하였고, 추가 별도 확인2실시예 1에서 설명하는 것과 같이 결정된 저해 농도 |
Claims (20)
- 화학친화성 물질 수용체 길항제를 확인하는 방법에 있어서,화학친화성 물질 수용체를 가지는 세포를 후보 길항제와 함께 배양시키고,화학친화성 물질 길항제의 리간드 저해 농도를 세포에 접촉시키고,세포 이동을 검사하여, 세포가 이동되었다는 것은 후보 길항물질이 길항제라는 것을 말해주는 것을 특징으로 하는 방법.
- 제 1 항에 있어서, 후보 길항제는 작은 펩티드, 펩티드-유사 분자, 비-펩티드성 유기 화합물, 무기 화합물, 핵산 또는 항체인 것을 특징으로 하는 방법.
- 제 1 항에 있어서, 화학친화성 물질 수용체용 리간드의 저해 농도에서는 최대 리간드-활성화된 세포 이동의 50%이상 수준으로 세포 이동을 저해시키는 것을 특징으로 하는 방법.
- 제 1 항에 있어서, 화학친화성 물질 수용체용 리간드의 저해 농도에서는 최대 리간드-활성화된 세포 이동의 95%이상 수준으로 세포 이동을 저해시키는 것을 특징으로 하는 방법.
- 제 1 항에 있어서, 화학친하성 물질 수용체용 리간드의 저해 농도에서는 최대 리간드-활성화된 세포 이동의 100%이상 수준으로 세포 이동을 저해시키는 것을 특징으로 하는 방법.
- 케모킨 수용체 길항제를 확인하는 방법에 있어서,케모킨 수용체를 가지는 세포를 후보 길항제와 함께 배양시키고,케모킨 수용체의 리간드 저해 농도를 세포에 접촉시키고,세포 이동을 검사하여, 세포가 이동되었다는 것은 후보 길항물질이 길항제라는 것을 말해주는 것을 특징으로 하는 방법.
- 제 6 항에 있어서, 후보 길항제는 작은 펩티드, 펩티드-유사 분자, 비-펩티드성 유기 화합물, 무기 화합물, 핵산 또는 항체인 것을 특징으로 하는 방법.
- 제 6 항에 있어서, 케모킨 수용체는 케모킨 수용체의 CCR, CXCR, CX3CR, XCR 류로 구성된 군에서 선택되는 것을 특징으로 하는 방법.
- 제 8 항에 있어서, 케모킨 수용체는 CXCR 1, CXCR 2, CXCR 3, CXCR 4, CXCR 5, CCR 1, CCR 2, CCR 3, CCR 4, CCR 5, CCR 6, CCR 7, CCR 8, CCR 9, CCR 10, CCR 11, CX3CR1, XCR1인 것을 특징으로 하는 방법.
- 제 6 항에 있어서, 케모킨는 CCR, CXCR, CX3CR 리간드로 구성된 군에서 선택되는 것을 특징으로 하는 방법.
- 제 10 항에 있어서, 케모킨은 IL-8, GCP-2, Gro α, Gro β, Gro γ, ENA-78, PBP, MIG, IP-10, I-TAC SDF-1(PBSF), BLC(BCA-1), MIP-1α, MIP-1β, RANTES, HCC-1,-2,-3 and -4, MCP-1,-2,-3, and -4, eotaxin-1, eotaxin-2, TARC, MDC, MIP-3α(LARC), MIP-3β(ELC), 6Ckine(LC) I-309, TECK, 임포택틴, 프랙트알킨(뉴우로택틴), TCA-4, Exodus-2, Exodus-3, CKβ-11이 되는 것을 특징으로 하는 방법.
- 제 6 항에 있어서, 케모킨 수용체는 CCR5이고, 케모킨은 MIP-1α, MIP-1β 또는 RANTES로 구성된 것을 특징으로 하는 방법.
- 제 6 항에 있어서, 케모킨 수용체는 CXCR4이고 케모킨은 SDF-1인 것을 특징으로 하는 방법.
- 제 6 항에 있어서, 케모킨 수용체는 CCR7이고 케모킨은 MIP-3β, ELC, 6Ckine인 것을 특징으로 하는 방법.
- 제 6 항에 있어서, 화학친화성 물질 수용체용 리간드의 저해 농도에서는 최대 리간드-활성화된 세포 이동의 50%이상 수준으로 세포 이동을 저해시키는 것을 특징으로 하는 방법.
- 제 6 항에 있어서, 화학친화성 물질 수용체용 리간드의 저해 농도에서는 최대 리간드-활성화된 세포 이동의 95%이상 수준으로 세포 이동을 저해시키는 것을 특징으로 하는 방법.
- 제 6 항에 있어서, 화학친하성 물질 수용체용 리간드의 저해 농도에서는 최대 리간드-활성화된 세포 이동의 100%이상 수준으로 세포 이동을 저해시키는 것을 특징으로 하는 방법.
- 세포 이동 장치 및케모킨 수용체를 보유하는 세포의 케모킨 저해농도의 용액으로 구성된 것을 특징으로 하는 키트.
- 제 18 항에 있어서 용액은 동결건조된 것을 특징으로 하는 키트.
- 케모킨 수용체 길항제를 확인하는 방법에 있어서통상적인 검사에서 케모킨 수용체의 후보 길항물질을 확인하고,제 2 단계로케모킨 수용체를 가지는 세포를 후보 길항제와 함께 배양시키고,케모킨 수용체의 리간드 저해 농도를 세포에 접촉시키고,세포 이동을 검사하여, 세포가 이동되었다는 것은 후보 길항물질이 길항제라는 것을 말해주는 것을 특징으로 하는 방법.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29668201P | 2001-06-07 | 2001-06-07 | |
US60/296,682 | 2001-06-07 | ||
US10/154,399 | 2002-05-22 | ||
PCT/US2002/016325 WO2002101350A2 (en) | 2001-06-07 | 2002-05-22 | Cell migration assay |
US10/154,399 US7282338B2 (en) | 2001-06-07 | 2002-05-22 | Cell migration assay |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020067007834A Division KR100635703B1 (ko) | 2001-06-07 | 2002-05-22 | 세포 이동성 검사 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040012888A true KR20040012888A (ko) | 2004-02-11 |
KR100598309B1 KR100598309B1 (ko) | 2006-07-10 |
Family
ID=26851415
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020037015768A KR100598309B1 (ko) | 2001-06-07 | 2002-05-22 | 세포 이동성 검사 |
KR1020067007834A KR100635703B1 (ko) | 2001-06-07 | 2002-05-22 | 세포 이동성 검사 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020067007834A KR100635703B1 (ko) | 2001-06-07 | 2002-05-22 | 세포 이동성 검사 |
Country Status (11)
Country | Link |
---|---|
US (3) | US7282338B2 (ko) |
EP (2) | EP1417488B1 (ko) |
JP (2) | JP4233092B2 (ko) |
KR (2) | KR100598309B1 (ko) |
AT (1) | ATE347695T1 (ko) |
CA (1) | CA2449628C (ko) |
DE (1) | DE60216606T2 (ko) |
DK (1) | DK1417488T3 (ko) |
ES (1) | ES2274041T3 (ko) |
HK (1) | HK1065844A1 (ko) |
WO (1) | WO2002101350A2 (ko) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE347695T1 (de) * | 2001-06-07 | 2006-12-15 | Chemocentryx Inc | Zellwanderungsassay |
AU2003267088A1 (en) * | 2002-09-11 | 2004-04-30 | Medical College Of Georgia Research Institute, Inc. | Chemokine receptor antagonists as therapeutic agents |
AU2003291549A1 (en) * | 2002-11-15 | 2004-06-15 | Morehouse School Of Medicine | Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms |
ES2369720T5 (es) | 2002-11-18 | 2014-11-06 | Chemocentryx, Inc. | Arilsulfonamidas |
EP1715033A4 (en) * | 2004-02-13 | 2008-06-11 | Asahi Techno Glass Corp | MEANS FOR PREPARING NOURISHED CELLS FOR EMBRYONIC STEM CELLS AND NOURISHED CELLS |
US7622583B2 (en) | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
US20060173019A1 (en) | 2005-01-14 | 2006-08-03 | Solomon Ungashe | Heteroaryl sulfonamides and CCR2 |
US8519135B2 (en) | 2006-07-14 | 2013-08-27 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2/CCR9 |
PL2046762T3 (pl) | 2006-07-14 | 2011-07-29 | Chemocentryx Inc | Triazolilofenylobenzenosulfonamidy |
KR101561652B1 (ko) * | 2006-07-18 | 2015-10-20 | 녹손 파르마 아게 | Sdf-1 결합형 c형 핵산분자 |
CN101820881B (zh) | 2007-07-12 | 2013-05-01 | 坎莫森特里克斯公司 | 作为ccr2调节剂用于治疗炎症的稠合杂芳基吡啶基和苯基苯磺酰胺 |
BRPI0815094B8 (pt) * | 2007-08-06 | 2023-04-18 | Noxxon Pharma Ag | Uso de uma molécula de ácido l-nucleico ligada a sdf-1 |
ES2678497T3 (es) | 2010-09-09 | 2018-08-13 | Noxxon Pharma Ag | Ácidos nucleicos que se unen a SDF-1 y su uso en el tratamiento del cáncer |
PE20180249A1 (es) | 2010-11-19 | 2018-02-02 | Eisai Randd Man Co Ltd | Anticuerpos neutralizadores anti-ccl20 |
CN104849377A (zh) * | 2015-01-29 | 2015-08-19 | 衢州市质量技术监督检测中心 | 一种气质法快速测定畜禽肉中β-***的前处理方法 |
JP7013464B2 (ja) | 2016-11-23 | 2022-02-15 | ケモセントリックス, インコーポレイテッド | 巣状分節性糸球体硬化症を治療する方法 |
JOP20190187A1 (ar) | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
US10758540B2 (en) | 2017-10-11 | 2020-09-01 | Chemocentryx, Inc. | Treatment of focal segmental glomerulosclerosis with CCR2 antagonists |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5811128A (en) | 1986-10-24 | 1998-09-22 | Southern Research Institute | Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor |
US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
US5284753A (en) | 1991-03-20 | 1994-02-08 | Neuro Probe, Inc. | Multiple-site chemotactic test apparatus and method |
SE9600820D0 (sv) * | 1996-03-01 | 1996-03-01 | Pharmacia Ab | Antibodies and their use |
US5928881A (en) * | 1996-07-11 | 1999-07-27 | Smithkline Beecham Corporation | Method of identifying agonists and antagonist for CC-CKR5 receptor |
GB9617923D0 (en) * | 1996-08-28 | 1996-10-09 | Smithkline Beecham Plc | Novel receptor |
US6153441A (en) * | 1998-02-17 | 2000-11-28 | Smithkline Beecham Corporation | Methods of screening for agonists and antagonists for human CCR7 receptor and CKβ-9 ligand and interaction thereof |
US6312689B1 (en) * | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
US6649158B1 (en) * | 1998-10-15 | 2003-11-18 | Canji, Inc. | Methods and compositions to induce antitumor response |
WO2000031261A2 (en) | 1998-11-25 | 2000-06-02 | Cadus Pharmaceutical Corporation | Methods and compositions for identifying effectors of the formyl peptide receptor like-1 (fprl-1) receptor |
US6329159B1 (en) * | 1999-03-11 | 2001-12-11 | Millennium Pharmaceuticals, Inc. | Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function |
JP2003502282A (ja) * | 1999-04-08 | 2003-01-21 | ザ ゼネラル ホスピタル コーポレーション | ヒト転移性細胞の作用因子源から離れた意図された移動 |
ATE347695T1 (de) * | 2001-06-07 | 2006-12-15 | Chemocentryx Inc | Zellwanderungsassay |
-
2002
- 2002-05-22 AT AT02739361T patent/ATE347695T1/de active
- 2002-05-22 EP EP02739361A patent/EP1417488B1/en not_active Expired - Lifetime
- 2002-05-22 US US10/154,399 patent/US7282338B2/en not_active Expired - Lifetime
- 2002-05-22 KR KR1020037015768A patent/KR100598309B1/ko active IP Right Grant
- 2002-05-22 DE DE60216606T patent/DE60216606T2/de not_active Expired - Lifetime
- 2002-05-22 JP JP2003504063A patent/JP4233092B2/ja not_active Expired - Lifetime
- 2002-05-22 EP EP06017100A patent/EP1717583A3/en not_active Withdrawn
- 2002-05-22 WO PCT/US2002/016325 patent/WO2002101350A2/en active IP Right Grant
- 2002-05-22 ES ES02739361T patent/ES2274041T3/es not_active Expired - Lifetime
- 2002-05-22 DK DK02739361T patent/DK1417488T3/da active
- 2002-05-22 CA CA002449628A patent/CA2449628C/en not_active Expired - Lifetime
- 2002-05-22 KR KR1020067007834A patent/KR100635703B1/ko active IP Right Grant
-
2004
- 2004-11-08 HK HK04108760A patent/HK1065844A1/xx not_active IP Right Cessation
-
2005
- 2005-01-24 US US11/041,858 patent/US20050186556A1/en not_active Abandoned
-
2007
- 2007-04-17 US US11/788,334 patent/US7396653B2/en not_active Expired - Lifetime
-
2008
- 2008-06-18 JP JP2008158580A patent/JP4340713B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO2002101350A3 (en) | 2004-03-11 |
JP4340713B2 (ja) | 2009-10-07 |
US7282338B2 (en) | 2007-10-16 |
EP1417488B1 (en) | 2006-12-06 |
US20050186556A1 (en) | 2005-08-25 |
WO2002101350A2 (en) | 2002-12-19 |
ATE347695T1 (de) | 2006-12-15 |
EP1417488A4 (en) | 2004-07-14 |
EP1717583A3 (en) | 2007-10-10 |
JP4233092B2 (ja) | 2009-03-04 |
CA2449628A1 (en) | 2002-12-19 |
US20030017485A1 (en) | 2003-01-23 |
KR100635703B1 (ko) | 2006-10-17 |
KR20060054488A (ko) | 2006-05-22 |
KR100598309B1 (ko) | 2006-07-10 |
DK1417488T3 (da) | 2007-03-05 |
EP1717583A2 (en) | 2006-11-02 |
JP2005518184A (ja) | 2005-06-23 |
US7396653B2 (en) | 2008-07-08 |
DE60216606D1 (de) | 2007-01-18 |
EP1417488A2 (en) | 2004-05-12 |
CA2449628C (en) | 2008-05-06 |
HK1065844A1 (en) | 2005-03-04 |
ES2274041T3 (es) | 2007-05-16 |
US20070196855A1 (en) | 2007-08-23 |
DE60216606T2 (de) | 2007-04-05 |
JP2009000113A (ja) | 2009-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7396653B2 (en) | Cell migration assay | |
US7468253B2 (en) | Method for multiple chemokine receptor screening for antagonists using RAM assay | |
Pelletier et al. | Presentation of chemokine SDF-1α by fibronectin mediates directed migration of T cells | |
Sachpatzidis et al. | Identification of allosteric peptide agonists of CXCR4 | |
Rodríguez-Frade et al. | Similarities and Differences in RANTES-and (AOP)-RANTES–triggered Signals: Implications for Chemotaxis | |
Brandes et al. | Activation-dependent modulation of B lymphocyte migration to chemokines | |
Muri et al. | Autoantibodies against chemokines post-SARS-CoV-2 infection correlate with disease course | |
Soriano et al. | Functional inactivation of CXC chemokine receptor 4–mediated responses through SOCS3 up-regulation | |
Lehmann et al. | HIV-1 Nef upregulates CCL2/MCP-1 expression in astrocytes in a myristoylation-and calmodulin-dependent manner | |
Ikegawa et al. | Elevated plasma stromal cell-derived factor 1 protein level in the progression of HIV type 1 infection/AIDS | |
US6858400B2 (en) | Detection of surface-associated human leukocyte elastase | |
EP1255112A2 (en) | Treatment of T-cell mediated diseases | |
Ma et al. | Inhibitory effects of chloroquine on the activation of plasmacytoid dendritic cells in SIVmac239-infected Chinese rhesus macaques | |
AU2003266749B2 (en) | Method for Multiple Chemokine Receptor Screening for Antagonists Using RAM Assay | |
AU2002312014A1 (en) | Cell migration assay | |
CA2452254C (en) | Method for multiple chemokine receptor screening for antagonists using ram assay | |
AU2006200356A1 (en) | Method for multiple chemokine receptor screening for antagonists using RAM assay | |
Ott et al. | A high-throughput chemotaxis assay for pharmacological characterization of chemokine receptors: Utilization of U937 monocytic cells | |
Taub et al. | Biological responses to chemokine superfamily members | |
Kershaw et al. | Analysis of chemokine receptor endocytosis and intracellular trafficking | |
Mack et al. | Downmodulation and recycling of chemokine receptors | |
Islam et al. | Chemokine and chemokine receptor analysis | |
Jinquan | IDENTIFICATION OF CHEMOATTRACTANTS FOR LYMPHOCYTE CHEMOTAXIS. | |
Peck | An ELISA method for quantitation of macrophage migration from agarose microdroplets | |
Taub | Modified microchemotaxis assays |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
A107 | Divisional application of patent | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130531 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20140529 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20150430 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20160330 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20170330 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20180416 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20190327 Year of fee payment: 14 |